Eli Lilly and Company (LLY)vsRegentis Biomaterials Ltd. (RGNT)
LLY
Eli Lilly and Company
$1,417.72
+0.61%
HEALTHCARE · Cap: $1.26T
RGNT
Regentis Biomaterials Ltd.
$1.37
0.00%
HEALTHCARE · Cap: $8.85M
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
RGNT
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : RGNT
The strongest argument for RGNT centers on Price/Book.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : RGNT
The primary concerns for RGNT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while RGNT is a value play — different risk/reward profiles.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 26/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Regentis Biomaterials Ltd.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Regent Assisted Living Inc. is a leading provider of premium assisted living and memory care services, committed to enhancing the quality of life for seniors through customized care and supportive living environments. With a nationwide network of facilities, Regent distinguishes itself through modern amenities and a compassionate, professional staff dedicated to resident well-being. By employing innovative care models and fostering strong community ties, the company consistently elevates its service offerings in a burgeoning senior living market. As the demand for senior care solutions continues to rise, Regent's strategic growth initiatives present a compelling investment opportunity for institutional investors seeking to capitalize on trends within the expanding healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?